Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

October 17, 2022

1 minute read

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

Starbucks Q3 Earnings Preview: Estimates, Analyst Price Targets And Key Items To Watch

August 1, 11:01 AM

Coffee giant Starbucks Corporation (NASDAQ: SBUX) is set to report third-quarter (Q3) financial results after market close Tuesday.

November 4, 5:06 AM

Piper Sandler analyst Arvind Ramnani maintains EPAM Sys (NYSE:EPAM) with a Overweight and lowers the price target from $419 to $414.

June 6, 5:32 PM

O’Reilly Automotive (NASDAQ:ORLY) has outperformed the market over the past 5 years by 16.51% on an annualized basis…

August 25, 12:36 PM

On Thursday, 63 companies set new 52-week lows.